OutSense is a technology company.
OutSense has raised $2.0M across 1 funding round.
OutSense has raised $2.0M in total across 1 funding round.
OutSense Diagnostics is a healthtech startup that builds a patented IoT device clipping onto standard toilet bowls to analyze human waste using optical sensors and AI, enabling early detection of medical conditions like colorectal cancer, urinary tract infections (UTI), diarrhea, dehydration, and constipation.[1][3][4] It serves patients, caregivers, healthcare providers, and organizations by delivering personalized diagnostics, biofeedback reports via a mobile app, and integration with Health Information Systems (HIS), solving the problem of non-invasive, continuous health monitoring without user intervention.[1][3] The company, founded in 2016 and headquartered in Or Yehuda, Israel, has raised $2.7 million in funding and holds patents supporting its unique database on human physiology extracts.[1][3]
OutSense was founded in 2016 in Or Yehuda, Israel, by Ishay Attar, who serves as Founder and Chairman.[3] Key team members include CEO and Director Yfat Scialom, CSO Tali Triebitz, and CTO Yaara Kapp-Barnea, bringing expertise in leadership, science, and technology to drive the company's healthtech innovations.[3] The idea emerged from recognizing the untapped potential of human waste analysis for proactive health insights, leading to the development of a novel optical sensor device that scans waste autonomously and processes data via AI algorithms in a secure cloud platform, incorporating patient medical history for tailored results.[1][3][4] Early traction includes securing funding, patents, and awards as of August 2023, establishing it as an active player in medical diagnostics.[1][3]
(Note: A separate Japanese company named OUTSENSE Inc. focuses on origami engineering for product development, unrelated to this diagnostics firm.[2])
OutSense rides the wave of AI-driven preventive healthtech and IoT wearables, capitalizing on trends in personalized medicine and remote monitoring accelerated by post-pandemic demand for at-home diagnostics.[1][3][4] Timing is ideal amid rising chronic disease prevalence (e.g., colorectal cancer) and aging populations needing non-invasive tools, with market forces like AI advancements in imaging and cloud analytics favoring scalable solutions over traditional diagnostics.[1][3] It influences the ecosystem by pioneering toilet-based biomarkers, potentially expanding to broader physiology insights and inspiring competitors like Aloe Care Health or Itamar Medical in seamless health integration.[3]
OutSense is poised for growth through clinical expansions, partnerships with healthcare providers, and new condition detections leveraging its AI database and patents. Trends like AI personalization and IoT ubiquity will amplify its momentum, potentially evolving it into a standard in home health monitoring. As non-invasive tech reshapes diagnostics, OutSense could significantly impact early intervention, building on its innovative foundation to deliver proactive health safeguards at scale.[1][3]
OutSense has raised $2.0M in total across 1 funding round.
OutSense's investors include Peregrine Ventures.
OutSense has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Series A in November 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2020 | $2.0M Series A | Peregrine Ventures |